MCHR1

Across TCGA pan-cancer cohorts, MCHR1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MCHR1 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher MCHR1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MCHR1 expression acts as an unfavorable survival marker.

DLBC, BLCA, and LIHC are the cancer types where MCHR1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
BLCA	DFS	Median	III,IV	0.171	0.550	.003	27	view →
LIHC	DFS	Median	III,IV	0.076	0.360	.001	12	view →
LUSC	OS	Median	All	0.313	0.732	.005	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MCHR1–DLBC (OS)

Open the DLBC breakdown →